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Abstract
Background: Expression of the stem cell marker octamer 4 (Oct-4) in various neoplasms has been previously
reported, but very little is currently known about the potential function of Oct-4 in this setting. The purpose of this
study was to assess the prognostic value of Oct-4 expression after surgery in primary non-small cell lung cancer
(NSCLC) and investigate its possible molecular mechanism.
Methods: We measured Oct-4 expression in 113 NSCLC tissue samples and three cell lines by
immunohistochemical staining and RT-PCR. The association of Oct-4 expression with demographic characteristics,
proliferative marker Ki67, microvessel density (MVD), and expression of vascular endothelial growth factor (VEGF)
were assessed.
Results: Oct-4 expression was detected in 90.3% of samples and was positively correlated with poor differentiation
and adenocarcinoma histology, and Oct-4 mRNA was found in each cell lines detected. Overexpression of Oct-4
had a strong association with cells proliferation in all cases, MVD-negative, and VEGF-negative subsets. A Kaplan-
Meier analysis showed that overexpression of Oct-4 was associated with shorter overall survival in all cases,
adenocarcinoma, squamous cell carcinoma, MVD-negative, and VEGF-negative subsets. A multivariate analysis
demonstrated that Oct-4 level in tumor tissue was an independent prognostic factor for overall survival in all cases,
MVD-negative, and VEGF-negative subsets.
Conclusion: Our findings suggest that, even in the context of vulnerable MVD status and VEGF expression,
overexpression of Oct-4 in tumor tissue represents a prognostic factor in primary NSCLC patients. Oct-4 may maintain
NSCLC cells in a poorly differentiated state through a mechanism that depends on promoting cell proliferation.
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Background
Despite recent progress in treatment, lung cancer
remains the leading cause of cancer deaths in both
women and men throughout the world [1]. Not all
patients with lung cancer benefit from routine surgery
and chemotherapy. This is especially true for those with
primary non-small cell lung cancer (NSCLC), the most
common malignancy in the thoracic field, where such
therapies have been tried with limited efficacy [2]. To
improve patient survival rate, researchers have increas-
ingly focused on understanding specific characteristics
of NSCLCs as a means to elucidate the mechanism of
tumor development and develop possible targeted thera-
peutic approaches.
Octamer 4 (Oct-4), a member of the POU-domain
transcription factor family, is normally expressed in
both adult and embryonic stem cells [3,4]. Recent
reports have demonstrated that Oct-4 is not only
involved in controlling the maintenance of stem cell
pluripotency, but is also specifically responsible for the
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any medium, provided the original work is properly cited.unlimited proliferative potential of stem cells, suggesting
that Oct-4 functions as a master switch during differen-
tiation of human somatic cell [5-7]. Interestingly, Oct-4
is also re-expressed in germ cell tumors [8], breast can-
cer [9], bladder cancer [10], prostate cancer and hepato-
mas [11,12], but very little is known about its potential
function in malignant disease [13]. Moreover, overex-
pression of Oct-4 increases the malignant potential of
tumors, and downregulation of Oct-4 in tumor cells
inhibits tumor growth, suggesting that Oct-4 might play
a key role in maintaining the survival of cancer cells
[13,14]. Although its asymmetric expression may indi-
cate that Oct-4 is a suitable target for therapeutic inter-
vention in adenocarcinoma and bronchioloalveolar
carcinoma [15], the role of Oct-4 expression in primary
NSCLC has remained ill defined.
To address this potential role, we assessed Oct-4
expression in cancer specimens from 113 patients with
primary NSCLC by immunohistochemical staining. We
further investigated the association of Oct-4 expression
in NSCLC tumor cells with some important clinical
pathological indices. In addition, we examined the invol-
vement of Oct-4 in tumor cell proliferation and tumor-
induced angiogenesis in NSCLC by relating Oct-4
expression with microvessel density (MVD), and expres-
sion of Ki-67 and vascular endothelial growth factor
(VEGF), proliferative and the vascular markers, respec-
tively. On the basis of previous reports that a subset of
NSCLC tumors do not induce angiogenesis but instead
co-opt the normal vasculature for further growth
[16,17], we also evaluated associations of Oct-4 expres-
sion with tumor cell proliferation and prognosis in sub-
sets of patients with weak VEGF-mediated angiogenesis
(disregarding the nonangiogenic subsets of NSCLC in
the analysis, which would tend to obscure the role of
Oct-4 expression in primary NSCLC).
Our results provide the first demonstration that
expression of the stem cell marker Oct-4 maintains
tumor cells in a poorly differentiated state through a
mechanism that depends on promoting cell prolifera-
tion. Moreover, even in the context of vulnerable MVD
status and VEGF expression, Oct-4 plays an important
role in tumor cell proliferation and contributes to poor
prognosis in human NSCLC.
Methods
Patients and tissue specimens
Cancer tissue and corresponding adjacent normal tissue
(within 1-2 cm of the tumor edge) from 113 primary
NSCLC cases were randomly selected from our tissue
database. Patients had been treated in the Department of
Thoracic Surgery of the First Affiliated Hospital of Sun
Yat-sen University from Jan 2003 to July 2004. None of
the patients had received neoadjuvant chemotherapy or
radiotherapy. Clinical information was obtained by
reviewing the perioperative medical records, or by tele-
phone or written correspondence. Cases were staged
according to the tumor-node-metastases (TNM) classifi-
cation of the International Union Against Cancer, revised
in 2002 [18]. The study was approved by the Medical
Ethical Committee of the First Affiliated Hospital, Sun
Yat-sen University. Paraffin-embedded specimens of each
case were sectioned and fixed on siliconized slides. Histo-
logical typing was determined according to World Health
Organization classifications [19]. Tumor size and meta-
static lymph node number and locations were obtained
from pathology reports.
Cell lines
The primary NSCLC cell lines, A549, H460 and H1299,
obtained from the Cell Bank of the Chinese Academy of
Science (Shanghai, China), were cultured in RPMI 1640
medium (Gibco/Invitrogen, Camarillo, CA, USA) sup-
plemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA).
Immunohistochemical staining and evaluation
The primary antibodies used in this study were as follow:
anti-Oct-4 (sc-5279, dilution 1:100; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), anti-Ki-67 (ab92742, dilu-
tion 1:200; Abcam, Cambridge, UK), and anti-VEGF
(sc-7269, dilution 1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Immunohistochemical staining was car-
ried out using the streptavidin-peroxidase method. Cells
with nuclear staining for Oct-4 and Ki-67, and cytoplas-
m i cs t a i n i n gf o rV E G F ,w e r es c o r e da sp o s i t i v ef o rt h e
respective marker. The intensity of Oct-4, Ki-67, and
VEGF staining was scored on a 0-to-3 scale: 0, negative;
1, light; 2, moderate; and 3, intense. The percentage of
the tumor area stained for each marker at each intensity
was calculated by dividing the number of tumor cells
positive for the marker at each intensity by the total
number of tumor cells. Areas that were negative were
given a value of 0. A total of 10-12 discrete foci in each
section were examined microscopically (400× magnifica-
tion) to generate an average staining intensity and per-
centage of the surface area covered. The final histoscore
was calculated using the formula: [(1 × percentage of
weakly positive tumor cells) + (2 × percentage of moder-
ately positive tumor cells) + (3 × percentage of intense
positive tumor cells)]. The median values of Oct-4, Ki-67,
and VEGF histoscores were used to classify samples as
positive (above the median) or negative (below the med-
ian) for each marker.
Evaluation of MVD
Immunohistochemical staining for CD34 (MS-363, dilu-
tion 1:50; Lab Vision, Fremont, CA; Clone QBEnd/10)
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ized areas within a tumor ("hot spots”) at low magnifica-
tion (×40), vessels in three representative fields in each
of these areas were counted at high magnification
(×400; 0.152 mm
2; 0.44 mm diameter). The high-magni-
fication fields were then marked for subsequent image
cell counting analysis. Single immunoreactive endothe-
lial cells or endothelial cell clusters separated from other
microvessels were counted as individual microvessels.
Endothelial staining in large vessels with tunica media
and nonspecific staining of non-endothelial structures
were excluded from microvessel counts. The mean
visual microvessel density for CD34 was calculated as
the average of six counts (three hot spots and three
microscopic fields). Microvessel counts greater than the
median counts were taken as MVD-positive, and micro-
vessel counts lower than the median were taken as
MVD-negative.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured cells using the
TRIzol reagent (Invitrogen, Grand Island NY, USA),
according to the manufacturer’s instructions. Extracted
RNA was treated with DNase (Fermentas, Vilnius, Lithua-
nia) to remove DNA contamination. For cDNA synthesis,
1 μg of total RNA was reverse transcribed using a Rever-
tAid First Strand cDNA Synthesis Kit (Fermentas). PCR
was performed with ExTaq (TaKaRa, Japan). The primer
sequences and sizes of amplified products were as follows:
Oct-4, 5’-GAC AGG GGG AGG GGA GGA GCT AGG-
3’ and 5’-CTT CCC TCC AAC CAG TTG CCC CAA
AC-3’ (142 bp); b-actin (internal control), 5’-GTG GGG
CGC CCC AGG CAC CA-3’ and 5’-CTC CTT AAT GTC
ACG CAC GAT TTC-3’ (540 bp).
Statistical analysis
All calculations were done using SPSS V.14.0 software
(Chicago, IL, USA). Spearman’s coefficient of correla-
tion, Chi-squared tests, and Mann-Whitney tests were
used as appropriate. A multivariate model was used to
evaluate statistical associations among variables. A Cox
regression model was used to relate potential prognostic
factors with survival.
Results
Basic clinical information and tumor characteristics
A total of 113 NSCLC patients (82 male and 31 female)
were enrolled in the study; the mean age of study parti-
cipants was 57.2 ± 10.0 years (range, 35-78 years). There
were 58 cases of lung adenocarcinoma, 52 cases of squa-
mous cell carcinoma, and three cases of large cell carci-
noma. Twenty-seven cases were well differentiated, 34
cases were moderately differentiated, and 52 cases were
poorly differentiated. The cases were classified as stage I
(n = 30), stage II (n = 48), stage III (n = 18), and stage
I V( n=1 7 ) .O ft h e1 1 3c a s e s ,6 7h a dl y m p hn o d e
metastasis, according to surgery and pathology reports.
Analyses of patient data after a 5-year follow-up showed
that 77 patients had died; median survival was 21.0
months. As expected, median survival was longer for
stage I-II patients (22.0 mo) than stage III-IV patients
(13.0 mo; P = 0.001). There were no significant differ-
ences in survival according to gender, smoking history,
histology, or grading. The clinical characteristics of
study samples are shown in Table 1.
Association of Oct-4 expression with clinicopathological
characteristics of NSCLC patients
Immunohistochemical analyses demonstrated that Oct-4
was expressed in 90.3% of samples (102/113 cases), with
clear staining observed mostly in the nuclei of tumor cells;
alveolar and bronchial epithelial cells in tumor-adjacent
tissues were negative for Oct-4 staining (Figure 1). The
histoscores of Oct-4 expression were variable among indi-
vidual tumor samples. The mean Oct-4 histoscore was
31.32 ± 5.99 and the median histoscore was 25.80; this
latter value was selected to categorize patients into Oct-4-
positive (above the median) and -negative (below the
median) groups. Among the 56 Oct-4-negative cases, 11
samples exhibited no Oct-4 staining. The associations of
Oct-4-positive and -negative status with various clinical
and pathological characteristics of NSCLC are shown in
Table 1. Regarding to histoscores of Oct-4 staining, there
was prominent discrepancy between adenocarcinoma and
squamous cell carcinoma (39.40 ± 3.59 and 21.64 ± 2.47,
p = 0.008). There was significant association of Oct-4 his-
toscores among well, moderated, and poor differentiation
of tumor (15.69 ± 3.70, 24.27 ± 2.73, and 43.80 ± 3.49, p =
0.039), and quantification of staining also revealed that
these associations differed markedly in adenocarcinoma or
squamous cell carcinoma population (Figure 1H). There
were no associations between Oct-4 expression and malig-
nant local advance, lymph node metastasis, or TNM stage
of disease (Figure 1I).
Oct-4 expression in NSCLC cell lines
To better understand the expression status of Oct-4 in
NSCLC, we examined the expression of Oct-4 in the
NSCLC cell lines, A549, H460, and H1299. Oct-4 mRNA
was detected in each of these cell lines (Figure 1G).
Association of Oct-4 expression with malignant
proliferation according to differences in VEGF-mediated
angiogenesis
Intratumoral Ki-67 expression, a marker of malignant
proliferation, varied according to Oct-4 phenotype in
the population under study, with high Ki-67 expression
showing a significant association with positive Oct-4
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Features Total Oct-4 expression n (%)
a P c
2
Negative Positive
Gender 0.330 0.674
Male 82 42 (51.2) 40 (48.8)
Female 31 14 (45.2) 17 (54.8)
Age (yr)
b 0.348 1.082
≤58 54 24 (44.4) 30 (55.6)
> 58 59 32 (54.2) 27 (45.8)
Smoking 0.849 0.072
Yes 45 23 (51.1) 22 (48.9)
No 68 33 (48.5) 35 (51.5)
Histological type < 0.001 13.637
Adenocarcinoma 58 21 (36.2) 37 (63.8)
Squamous cell carcinoma 52 35 (67.3) 17 (32.7)
Large cell carcinoma 3 0 (0.0) 3 (100.0)
Histological differentiation 0.001 32.463
Well differentiated
c 27 24 (88.9) 3 (11.1)
Moderately differentiated 34 20 (58.8) 14 (41.2)
Poorly differentiated
d 52 12 (23.1) 40 (76.9)
Adenocarcinoma 0.001 17.324
Well differentiated
c 15 12 (80.0) 3 (20.0)
Moderately differentiated 14 4 (28.6) 10 (71.4)
Poorly differentiated 29 5 (17.2) 24 (82.8)
Squamous cell carcinoma 0.001 16.780
Well differentiated 12 12 (100.0) 0 (0.0)
Moderately differentiated 20 16 (80.0) 4 (20.0)
Poorly differentiated 20 7 (35.0) 13 (65.0)
Local advance 0.205 3.172
T1 30 17 (56.7) 13 (43.3)
T2 48 26 (54.2) 22 (45.8)
T3/T4 35 13 (37.1) 22 (62.9)
Lymph node metastasis 0.466 1.529
N0 46 22 (47.8) 24 (52.2)
N1 23 14 (60.9) 9 (39.1)
N2 44 20 (45.5) 24 (54.5)
Clinical stage 0.680 0.227
I/II 81 39 (48.1) 42 (51.9)
III/IV 32 17 (53.1) 15 (46.9)
MVD expression
a 0.348 1.082
Positive 59 32 (54.2) 27 (45.8)
Negative 54 24 (44.4) 30 (55.6)
VEGF expression
a 0.574 0.435
Positive 57 30 (52.6) 27 (47.4)
Negative 56 26 (46.4) 30 (53.6)
Ki-67 expression
a 0.001 16.430
Positive 54 16 (29.6) 38 (70.4)
Negative 59 40 (67.8) 19 (32.2)
aPatients were divided according to the median values of immunohistochemical histoscores
bPatients were divided according to median age
cBronchioloalveolar carcinoma was included in well differentiated
dLarge cell carcinoma was included in poorly differentiated
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that this association differed markedly depending on
Oct-4 histoscores (Figure 2A, p = 0.001) and showed
that these two markers were positively correlated (Figure
2B). In MVD-negative and VEGF-negative subsets, intra-
tumoral Ki-67 expression varied significantly according
to Oct-4 phenotype (Figure 2A); Ki-67 (Figure 2C) and
Oct-4 (Figure 2E) expression were also positively corre-
lated in these subsets. These results suggest a prominent
association of Oct-4 expression with malignant prolif-
eration in NSCLC, especially in cases with weak VEGF-
mediated angiogenesis.
Association of Oct-4 expression with survival in all cases
and in subsets of cases: univariate and multivariate
analyses
The strength of associations between each individual pre-
dictor and overall survival was shown by univariate and
multivariate analyses (Table 2). Oct-4 expression in
tumor tissue and differentiation of tumor cells were
strongly associated with cancer-associated death. Nota-
bly, an Oct-4 expression level less than the median histo-
score (25.80) was associated with improved survival (HR,
1.011), whereas elevated Oct-4 expression was associated
with shorter cumulative survival (p = 0.009). A Kaplan-
Meier plot showed a prominent difference in survival
estimates for patients with high versus low Oct-4 expres-
sion in tumor tissue; this difference corresponded to a
median survival of 18.2 ± 6.0 months for patients with
high Oct-4 expression compared with a median survival
of more than 24.7 ± 9.1 months for patients with low
Oct-4 expression (Figure 3A). More importantly, signifi-
cant differences were also found in the adenocarcinoma
subset (17.7 ± 9.1 vs. 27.3 ± 9.6 months; Figure 3B) and
the squamous cell carcinoma subset (20.7 ± 9.5 vs. 23.2 ±
10.8 months; Figure 3C). When all predictors were
included in a Cox model, Oct-4 expression retained its
prognostic significance for overall survival. Hence, a low
level of Oct-4 expression in tumor tissue predicted
improved survival in NSCLC patients.
Figure 1 Oct-4 expression in tissues of well-differentiated adenocarcinoma (A), well-differentiated squamous cell carcinoma (B), poorly
differentiated adenocarcinoma (C), and poorly differentiated squamous cell carcinoma (D), as well as VEGF staining (E) and MVD staining (F)
were demonstrated immunohistologically. Quantification of Oct-4 expression (Oct-4 histoscore) with respect to differentiation status or tumor
histology (G) and local advance or lymph nodes metastasis (H) is shown; 95% CIs are indicated.
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all survival in patients in which VEGF-mediated angio-
genesis was disabled, we also performed univariate and
multivariate analyses in MVD-negative and VEGF-nega-
tive subsets (Table 2). Notably, an Oct-4 expression
level less than the median histoscore was associated
with improved survival, whereas elevated Oct-4 expres-
sion was associated with shorter cumulative survival in
both the MVD-negative subset (HR, 1.024, p =0 . 0 0 5 )
and the VEGF-negative subset (HR, 1.011, p =0 . 0 4 2 ) .
Further, a Kaplan-Meier plot showed a prominent differ-
ence in survival estimates for patients in the MVD-nega-
tive subset, where the median survival for patients with
high Oct-4 expression was 18.5 ± 7.6 months compared
with a median survival of more than 24.3 ± 8.3 months
for patients with low Oct-4e x p r e s s i o n( F i g u r e3 D ) .
Similar differences were found for patients in the
VEGF-negative subset; here the median survival for
patients with high Oct-4 expression was 17.5 ± 6.1
months compared with a median survival of more than
21.9 ± 7.5 months for patients with low Oct-4 expres-
sion (Figure 3F). Hence, Oct-4 expression retained its
prognostic significance for overall survival in NSCLC
patients with weak VEGF-mediated angiogenesis.
Discussion
Although Oct-4 has been detected in various carcino-
mas, including breast cancer [9], bladder cancer [10],
prostate cancer [11] and lung adenocarcinoma [20], the
precise role of this stem cell marker in maintaining the
survival of cancer cells is unclear. Sustained expression
of Oct-4 in epithelial tissues has been shown to lead to
dysplastic changes through inhibition of cellular differ-
entiation, similar to its action in some progenitor cells,
suggesting that Oct-4 may play an important role in the
genesis of tumors [21]. However, the mechanisms by
which Oct-4 acts during tumor progression have
remained poorly understood. Accordingly, we examined
Figure 2 Ki-67 expression histoscores were significantly different (ANOVA) according to different Oct-4 status in all cases, and in
subsets of MVD-negative, MVD-positive, VEGF-negative, and VEGF-positive cases (A). All cases were divided into positive (above the
median histoscore) and negative (below the median histoscore) groups. The association of Oct-4 staining with Ki-67 expression was positive in
all cases (B), and in subsets of MVD-negative (C), MVD-positive (D), VEGF-negative (E), and VEGF-positive (F) cases. Statistical differences were
calculated using Pearson and Spearman correlation analysis.
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ing on the associations of Oct-4 expression with clinico-
pathological features and markers of tumor-induced
angiogenesis. Important in this context is the observa-
tion that, after disregarding nonangiogenic subsets of
NSCLC (which tend to obscure the association of Oct-4
with tumor angiogenesis), a subset of NSCLC tumors
does not induce angiogenesis, but instead co-opts the
normal vasculature for further growth.
On the basis of the previous finding that Oct-4 may
be a major contributor to the maintenance of self-
renewal in embryonic stem cells, we investigated the
association of Oct-4 expression with self-renewal of
NSCLC cells. The immunohistochemical analyses pre-
sented here showed clear Oct-4 staining in most sec-
tions, and RT-PCR showed Oct-4 mRNA in all NSCLC
cell lines. Our data extend the previous report of Oct-4
overexpression in lung adenocarcinoma [20], providing
the first demonstration that Oct-4 is also present in
lung squamous cell carcinoma specimens, exhibiting an
apparent difference in the degree of expression among
sections analyzed. One possible explanation for these
findings is that the genesis of lung adenocarcinoma and
squamous cell carcinoma may be different. The former
arises from mucous glands or the cells of bronchoalveo-
lar duct junction and the latter grows most commonly
in or around major bronchi. Further studies designed to
address the relationship between Oct-4 expression in
endothelial precursors and the sites of origin of adeno-
carcinoma and squamous cell carcinoma are required to
c o n f i r mt h i s .O u rd a t aa l s os h o w e dt h a tt h ed e g r e eo f
immunohistochemical staining was positively correlated
with poor differentiation of tumor cells and Ki-67
expression; this latter marker provides an opportunity to
analyze the proliferative cell fraction in preserved tumor
specimens. High levels of Oct-4 have been shown to
increase the malignant potential of tumors, whereas
inactivation of Oct-4 induces a regression of the malig-
nant component [22]; moreover, knockdown of Oct-4
expression in lung cancer cells has been shown to
Table 2 Univariate and multivariate analyses of individual variables for correlations with overall survival: cox
proportional hazards model
Variables Univariate Multivariate
HR 95%CI P HR 95%CI P
Age 0.988 0.969-1.008 0.231 1.001 0.978-1.025 0.922
Gender 0.852 0.517-1.405 0.530 0.525 0.305-0.906 0.121
Smoking 1.179 0.740-1.880 0.489 1.277 0.743-2.195 0.376
Histological type 1.087 0.697-1.695 0.713 1.168 0.706-1.932 0.546
Histological differentiation 3.727 2.139-6.495 < 0.001 3.666 1.937-6.939 0.001
Local advance 1.282 0.920-1.731 0.149 1.222 0.928-1.609 0.153
Lymph node metastasis 1.487 1.148-1.927 0.003 1.042 0.743-1.461 0.813
Oct-4 expression 1.105 1.007-1.024 < 0.001 1.011 1.003-1.020 0.009
Age 0.990 0.963-1.018 0.482 1.014 0.978-1.051 0.450
Gender 0.786 0.408-1.512 0.470 0.296 0.087-1.008 0.052
Smoking 1.231 0.646-2.346 0.527 0.733 0.237-2.265 0.590
Histological type 0.785 0.408-1.512 0.470 0.869 0.386-1.956 0.735
Histological differentiation 1.428 0.701-2.910 0.327 1.418 0.591-3.405 0.434
Local advance 1.191 0.780-1.817 0.418 0.934 0.560-1.558 0.793
Lymph node metastasis 1.217 0.833-1.778 0.310 1.560 0.976-2.495 0.063
Oct-4 expression 1.014 1.002-1.025 0.021 1.024 1.007-1.042 0.005
Age 0.994 0.965-1.024 0.688 1.005 0.967-1.044 0.801
Gender 0.790 0.395-1.580 0.505 0.401 0.166-0.966 0.096
Smoking 1.232 0.635-2.389 0.537 0.921 0.382-2.219 0.855
Histological type 1.439 0.767-2.700 0.257 1.247 0.598-2.600 0.556
Histological differentiation 1.925 0.934-3.969 0.076 1.962 0.791-4.868 0.146
Local advance 1.313 0.822-2.099 0.254 1.231 0.743-2.042 0.420
Lymph node metastasis 1.415 0.953-2.103 0.086 1.472 0.933-2.323 0.097
Oct-4 expression 1.010 0.999-1.022 0.018 1.011 0.998-1.024 0.042
Variable 1, Oct-4 expression was an independent prognostic factor, adjusted by histological differentiation, in all cases
Variable 2, Oct-4 expression was an independent factor in MVD-negative cases
Variable 3, Oct-4 expression was an independent factor in VEGF-negative cases
Abbreviations: HR, hazard ratio; CI, confidence interval
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CD133-negative cells [23]. These findings, taken
together with our data, indicate that overexpression of
Oct-4 in NSCLC tissues may maintain the poorly differ-
entiated state by contributing to tumor cell proliferation.
On the other hand, down-regulation of Oct-4 expression
Figure 3 Cumulative Kaplan-Meier survival curves based on the median values of Oct-4 immunochemical histoscores in NSCLC tissues
are showed for all cases (A), and for adenocarcinoma (B), squamous cell carcinoma (C), MVD-negative (D), MVD-positive (E), VEGF-negative (F),
and VEGF-positive (G) cases. All cases were divided into positive (above the median histoscore) and negative (below the median histoscore)
groups. Oct-4-positivity was associated with decreased overall survival in all subset. Statistical differences were calculated using log-rank
comparisons.
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cell-like cells through an Oct-4/Tcl1/Akt1 pathway,
implying that Oct-4 might maintain the survival of
tumor-initiating cells, at least in part, by inhibiting
apoptosis [13]. Whether an Oct-4-dependent pathway
modulates apoptosis in clinical NSCLC samples or
NSCLC cell lines has not yet been tested.
Previous reports have indicated that tumor-induced
angiogenesis is important in maintaining the poorly dif-
ferentiated state and promoting metastasis in NSCLC
[23,24]. In our study, we observed an association of
Oct-4 expression in NSCLC specimens with some fea-
tures of tumor-induced angiogenesis, but the investiga-
tion revealed no prominent linkage between Oct-4
expression and neovascularization (defined by CD34 and
VEGF-A expression). However, Passalidou and Pezzella
have previously described a subset of NSCLC without
morphological evidence of neo-angiogenesis. In these
tumors, alveoli are filled with neoplastic cells and the
only vessels present appeared to belong to the trapped
alveolar septa; moreover, tumors with normal vessels
and no neo-angiogenesis seemed resistant to some anti-
angiogenic therapies [16,17]. In this context, we
observed an association of Oct-4 expression with tumor
cell proliferation in patients with weak VEGF-mediated
angiogenesis, including MVD-negative and VEGF-nega-
tive subsets, indicating that Oct-4 still plays an impor-
tant role in cell proliferation in NSCLC tumors, even
those with weak MVD or VEGF status. Whether Oct-4
expression contributes to resistance to anti-angiogenic
therapy thus warrants additional research attention.
Although recent reports have also shown that Oct-4 is
re-expressed in different human carcinomas, implicating
Oct-4 as a potential diagnostic marker in malignancy
[25,26], whether Oct-4 expression can be used as a diag-
nostic tool to monitor the clinical prognosis of NSCLC
patients has not been previously substantiated. An ana-
lysis of our follow-up data designed to definitively assess
the effect of Oct-4 immunohistochemical expression on
the prognosis of NSCLC patients showed that the post-
operative survival duration of patients with high Oct-4
expression was notably shorter than that of patients
with low expression. These results indicate that overex-
pression of Oct-4 has a detrimental effect on prognosis,
and further demonstrates that Oct-4 expression may be
correlated with the malignant behavior of tumors during
NSCLC progression. A combined genomic analysis of
the Oct-4/SOX2/NANOG pathway has recently demon-
strated high prognostic accuracy in studies of patients
with multiple tumor types [27]. Similarly, multivariate
analyses of the data presented here demonstrated that
Oct-4 expression is an independent factor whose expres-
sion might indicate poor prognosis of patients with
NSCLC, generally, as well in NSCLC patient subsets,
especially those with weak or no neovascularization. A
detailed investigation of the association of Oct-4 expres-
sion with treatment response, particularly a characteriza-
tion of the molecular phenotype of tumors following
downregulation of Oct-4, would provide further support
for this interpretation.
Conclusion
In summary, a multivariate analysis demonstrated that
Oct-4 expression was an independent predictor of over-
all survival, suggesting that Oct-4 may be useful as a
molecular marker to assess the prognosis of patients
with primary NSCLC, especially those without promi-
nent neovascularization. In patients without prominent
tumor-induced angiogenesis, Oct-4-overexpressing cells
in primary NSCLC tissue represent a reservoir of tumor
cells with differentiation potential; moreover, Oct-4 may
maintain tumor cells in a poorly differentiated state
through a mechanism that depends on promoting cell
proliferation. The molecular mechanisms by which Oct-
4 sustains the self-renewal capacity of tumor cells, espe-
cially those with poor neovascularization status, are
poorly understood and are the focus of our future stu-
dies. Developing strategies to inhibit Oct-4 during
tumor progression may have positive prognostic impli-
cations in primary NSCLC patients.
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